Benzinga | Mar 11, 2021 07:35AM EST

Hepion Pharmaceuticals To Present On CRV431 And AI-POW At NASH-TAG 2021 Mar. 13

EDISON, NJ / ACCESSWIRE / March 11, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver disease, today announced that it will present at the NASH-TAG 2021 Conference, being held virtually on March 11-13.

The NASH-TAG Conference is designed to bring together clinicians and researchers in academia and the pharmaceutical industry for a focused interactive educational update highlighting the most relevant advances and challenges in the diagnosis and therapy of NASH and liver fibrosis.

An oral presentation, to be delivered by Hepion's CEO, Dr. Robert Foster, will review the positive top line data from the low dose cohort in the Company's Phase 2a 'AMBITION' clinical trial of CRV431, an oral, once daily novel cyclophilin inhibitor, as well as the planned use of its AI-POWR(tm) platform in conjunction with PK-PD (pharmacokinetics-pharmacodynamics) studies to enrich its Phase 2b study design and optimize it for outcomes.

Presentation Details

Title: CRV431 - Pancyclophilin Inhibitor

Session: New Pharmacological Targets

Date: Saturday, March 13, 2021

Time: 7:15 - 7:30 p.m. MT